Quest Magazine

Reflections from MDA’s New CEO on the Eve of the Show of Strength Telethon

August 31, 2013

The MDA telethon is an American tradition.

Grand Ole Opry Performance by Luke Bryan To Be Shown on MDA Show of Strength Telethon

DMD: Prosensa Announces New Grant and Provides Exon-Skipping Update

Dutch biotechnology company Prosensa, developer of experimental drugs to treat Duchenne muscular dystrophy (DMD) using exon skipping, announced encouraging developments in an Aug. 28, 2013, press release.

Austin Mahone To Perform on MDA Show of Strength Telethon

SMA: Full Speed Ahead

A Closer Look: SMA Slideshow

Paula Abdul To Give Special Presentation on MDA Telethon Labor Day Weekend

Study Probes Impact of Early-Onset MMD1

Communication difficulties, social role limitations, problems with mobility and walking, and cognitive impairment were the most frequently mentioned themes in open-ended interviews conducted with people affected by congenital-onset or childhood-onset type 1 myotonic muscular dystrophy (MMD1, or DM1) or their parents.

Darius Rucker To Perform Hit Single on MDA Show of Strength Telethon Labor Day Weekend

IBM: Novartis Drug Gets Breakthrough Therapy Designation from FDA

Multinational pharmaceutical company Novartis has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for BYM338, an experimental drug it is developing to treat sporadic inclusion-body myositis (IBM).

UPDATE: FDA Approves Testing Multiple Sclerosis Drug in ALS

The U.S. Food and Drug Administration (FDA) has given the go-ahead to the nonprofit biotech ALS Therapy Development Institute (ALS TDI) to conduct a clinical trial of TDI132  — also known as fingolimod, or the brand name Gilenya— in people withALS (amyotrophic lateral sclerosis).